Genelux Corp Files 8-K: Board Changes & Shareholder Votes
Ticker: GNLX · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1231457
| Field | Detail |
|---|---|
| Company | Genelux Corp (GNLX) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $5.00, $3.33, $6.00, $22.40 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, shareholder-vote
TL;DR
Genelux Corp filed an 8-K detailing board changes, executive compensation updates, and shareholder votes.
AI Summary
On August 27, 2025, Genelux Corporation announced changes in its board of directors and executive compensation. The company also reported on matters submitted to a vote of security holders. Specific details regarding the individuals involved, the nature of the votes, and the compensation adjustments were filed.
Why It Matters
This filing indicates significant corporate governance and potential strategic shifts within Genelux Corporation, which could impact its future direction and shareholder value.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can signal internal shifts that may affect company strategy and performance.
Key Numbers
- 001-41599 — Commission File Number (Identifies the company's SEC filing series.)
- 77-0583529 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Genelux Corporation (company) — Registrant
- August 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2625 Townsgate Road, Suite 230 (address) — Principal executive office address
- Westlake Village, California (location) — City and State of principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors or certain officers and the election of directors, but the specific names and details of these changes are not provided in the excerpt.
What were the key outcomes of the matters submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific proposals and their outcomes are not detailed in the provided text.
Were there any changes to executive compensation arrangements?
Yes, the filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, indicating potential changes or updates to executive compensation.
What is the primary business of Genelux Corporation?
Genelux Corporation is classified under the Pharmaceutical Preparations (SIC 2834) industry.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 27, 2025.
Filing Stats: 1,031 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-09-03 16:05:48
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar
- $5.00 — ) that had exercise prices greater than $5.00 per share as of the Effective Date (the
- $3.33 — ice for Eligible Options was reduced to $3.33 per share, the closing price of the Com
- $6.00 — lo, Chief Technical Officer 174,999 $6.00 - $22.40 Ralph Smalling, Head of Regu
- $22.40 — f Technical Officer 174,999 $6.00 - $22.40 Ralph Smalling, Head of Regulatory
Filing Documents
- form8-k.htm (8-K) — 54KB
- 0001641172-25-026390.txt ( ) — 219KB
- gnlx-20250827.xsd (EX-101.SCH) — 3KB
- gnlx-20250827_lab.xml (EX-101.LAB) — 33KB
- gnlx-20250827_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: September 3, 2025 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer